Generic biopharmaceutical drugs: an economic and policy analysis
- PMID: 23397414
- PMCID: PMC3564391
Generic biopharmaceutical drugs: an economic and policy analysis
Abstract
Encouraging both generic drug competition and pharmaceutical innovation is difficult, especially in the case of follow-on biologics. Can the U.S. nurture a system that seeks both lower drug prices now and new and improved medications in the future?
Figures
References
-
- Abate T. Generic biotech drugs on horizon. U.S. begins to consider issues as patents expire. San Francisco Chronicle. 2002 Jun 24;
-
- Ainsworth SJ. Biopharmaceuticals. Chemical and Engineering News. 2005;83:21–29.
-
- Alpert W. Biotech’s next challenge. Smart Money. Available online: « http://www.smartmoney.com/barrons/index.cfm?story=20060522». Accessed June 13, 2006.
-
- Anand G. Why Genzyme can charge so much for Cerezyme. Wall Street Journal. 2005 Nov. - PubMed
-
- Appleby J, Wolf R. Medicare cost projections drop. USA Today. 2006 Feb 2;:A4.
LinkOut - more resources
Full Text Sources